



GLAND PHARMA LIMITED

DETAILS OF FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTORS DURING THE FINANCIAL YEAR 2022-23

[Pursuant to Regulations 25(7) and 46 (2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

The Company firmly believes that the Board of Directors of the Company needs to be abreast with the knowledge of the latest updates and developments that may affect the industry and our business. With this view, the Company regularly updates the Board, including the Independent Directors, on the key developments in various areas of business, the latest advancements in the industry, and global markets. Relevant updates on statutory changes in industry-related laws that may impact the Company are circulated to the Directors. The Directors also visit the manufacturing and research facilities of the Company and interact with the management team during those visits, to have a better insight into the operations of the Company.

The Company conducts familiarization programmes in-house and through external agencies. The details of familiarization programmes conducted during the financial year 2022-23 and on a cumulative basis are as below.

(No. of hours)

S. No	Name of the Independent Director	Industry & Global Markets	Business Operations & Strategy	Facility Visits	Regulatory Updates and Roles and Responsibilities of Independent Directors	Total FY 2020-21(November 2020 to March 2021)	Total FY 2021-22	Total FY 2022-23	Cumulative
1	Mr. Yiu Kwan Stanley Lau	2	3	-	1	1	6	6	13
2	Mr. Udo Johannes Vetter	2	3	4	1	1	10	10	21
3	Mr. Essaji Goolam Vahanvati	2	3	-	1	1	6	6	13
4	Mr. Satyanarayana Murthy Chavali	2	3	4	1	1	7	10	18
5	Ms. Naina Lal Kidwai	2	4	4	1	1	8	11	20